High throughput screening for deep mining of antibody repertoires, Dr. Stefan Moese, Novartis, Switzerland
Supported by:
13 June 2018
ABOUT THIS WEBINAR
Antibodies are the key drivers of new drug development based on biologics rather than small molecules. Multiple blockbuster drugs have emerged in this area, many more are in the pipeline. In this webinar Stefan Moese talks about the implementation of a high throughput screening approach for mining of antibody repertoires at ESBATech.
Putting the screening activity in the context of the full drug discovery challenge, the theoretical concept is described and then its translation to a real research setting. Different analytical tools, such as flow cytometry of B-cells, immun-binding assays, cell based assays and more are discussed. The data challenge is also part of the webinar, and the automation used to execute the screening tasks in a high-throughput fashion is discussed.
The rest of this content is restricted - login or subscribe free to access
Thank you for visiting our website. To access this content in full you'll need to login. It's completely free to subscribe, and in less than a minute you can continue reading. If you've already subscribed, great - just login.
Why subscribe? Join our growing community of thousands of industry professionals and gain access to:
- quarterly issues in print and/or digital format
- case studies, whitepapers, webinars and industry-leading content
- breaking news and features
- our extensive online archive of thousands of articles and years of past issues
- ...And it's all free!
Click here to Subscribe today Login here
Related topics
Antibodies, Antibody Discovery, Assays, Biologics, Cell-based assays, Drug Development, Drug Discovery, Drug Discovery Processes, Flow Cytometry, Genomics, High Throughput Screening (HTS), Informatics, Screening, Sequencing, Stem Cells, Translational Science
Related organisations
Beckman Coulter Inc.
